

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2009337516 B2**

(54) Title  
**Image based clinical trial assessment**

(51) International Patent Classification(s)  
**G06T 7/00** (2006.01) **G06T 15/00** (2011.01)  
**G06Q 10/00** (2012.01)

(21) Application No: **2009337516** (22) Date of Filing: **2009.12.09**

(87) WIPO No: **WO10/082096**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>61/144,231</b>	<b>2009.01.13</b>	<b>US</b>

(43) Publication Date: **2010.07.22**

(44) Accepted Journal Date: **2015.05.21**

(71) Applicant(s)  
**University of Washington;Koninklijke Philips Electronics, N.V.**

(72) Inventor(s)  
**Thiele, Frank O.;Minoshima, Satoshi**

(74) Agent / Attorney  
**FB Rice, Level 23 44 Market Street, Sydney, NSW, 2000**

(56) Related Art  
**LORENZO-VADES, M. et al. "Atlas-Based Segmentation and Tracking of 3D Cardiac MR Images Using Non-rigid Registration." LNCS (Proceedings of Medical Image Computing and Computer-Assisted Intervention-MICCAI 2002), 2002, Vol. 2488, p. 642-650**  
**LEUNG, K. et al. "Automatic Quantification of Changes in Bone in Serial MR Images of Joints." IEEE Transactions on Medical Imaging, 2006, Vol. 25, No. 12, pages 1617-1626**



- (51) **International Patent Classification:**  
*G06T 7/00* (2006.01)
- (21) **International Application Number:**  
PCT/IB2009/055614
- (22) **International Filing Date:**  
9 December 2009 (09.12.2009)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/144,231 13 January 2009 (13.01.2009) US
- (71) **Applicants (for all designated States except US):** KONINKLIJKE PHILIPS ELECTRONICS, N.V. [NL/NL]; Groenewoudseweg 1, NL-5621 BA Eindhoven (NL). UNIVERSITY OF WASHINGTON [US/US]; 4311 11th Avenue NE, Seattle, Washington 98105 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** THIELE, Frank, O. [DE/US]; 595 Miner Road, Cleveland, Ohio 44143 (US). MINOSHIMA, Satoshi [JP/US]; 595 Miner Road, Cleveland, Ohio 44143 (US).
- (74) **Agent:** DAMEN, Daniel, M.; Philips Intellectual Property & Standards, High Tech Campus 44, P.O. Box 220, NL-5600 AE Eindhoven (NL).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
  - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) **Title:** IMAGE BASED CLINICAL TRIAL ASSESSMENT




Fig. 5

(57) **Abstract:** A method for assessing a treatment in a trial includes obtaining images generated from image data acquired at different times during a trial time period for a same region of interest of a subject. The treatment is administered to the subject for the trial. The method further includes co-registering the images and mapping the co-registered images to a reference image representing the region of interest. The method further includes generating a trial image of the region of interest showing at least one of structural or functional physiological changes that occurred during the trial time period based on the mapped co-registered images, and displaying the trial image.





---

**Published:**

**(88) Date of publication of the international search report:**

30 September 2010

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

## IMAGE BASED CLINICAL TRIAL ASSESSMENT

### DESCRIPTION

The following generally relates to assessing clinical trials using medical imaging data.

5

Clinical trials in healthcare provide information that is used to determine the clinical efficacy of a new drug or device. A typical drug trial involves several subjects, some of which ingest the drug under trial and others of which ingest a placebo. The subjects are monitored over time for physiological changes, which are hypothesized, in response to the drug. The change resulting from the drug or the degree of change between the two groups of subjects is analyzed and used to test the hypothesis and determine the efficacy of the new drug.

Medical imaging can be used to monitor structural and/or functional changes in the subject in response to the drug. By way of example, longitudinal imaging, which involves acquiring images of the same anatomy for the same subject over time allows for the investigation of the affect of the drug on the subject over time. Quantitative imaging procedures currently serve as surrogate endpoints in clinical trials. A standard procedure for quantitative brain imaging is statistical brain mapping. In statistical brain mapping, the brain image of a subject is statistically compared to a control collective of brain images.

15  
20

With one technique, a new drug is administered to some subjects and a placebo is administered to other subjects, and the subjects are scanned over time. The resulting images are spatially normalized to standard coordinates, and a statistical analysis is performed on the normalized images. The results can be mapped to a three dimensional model of the brain surface or a surface projected on the model. The statistical analysis may provide t-statistics or a z-score, which is a scalar value per voxel. A final image is rendered showing those voxels that have a statistical value above a given threshold. From such an image, the efficacy of the drug can be determined.

25

The literature notes that the cost of a clinical trial makes up as much as sixty percent (60%) of the total development cost of a new drug. A relatively high cost component of a trial is the number of subjects enrolled in the trial; more subjects leads to a more expensive trial. Lower variation results in higher statistical power, or a greater ability

30

of the trial to reliably detect the magnitude of the effect of the drug relative to the placebo. Unfortunately, the number of subjects enrolled in a particular trial generally depends on the variability (or noise) of the trial assessment technique, with the number of subjects required for a trial and, thus the cost of the trial, increasing with increased variability.

5 Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

10 Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application.

15 Aspects of the present application address the above-referenced matters and others.

20 According to one aspect, a method for assessing a treatment in a trial includes obtaining images generated from image data acquired at different times during a trial time period for a same anatomical region of a subject. The treatment is administered to the subject for the trial. The method further includes co-registering the images using a single transformation and mapping the co-registered images to a reference image representing the anatomical region. The method further includes generating a trial image of the anatomical region showing at least one of structural or functional physiological changes that occurred during the trial time period based on the mapped co-registered images, and displaying the trial image. The anatomical region may be scanned.

25 In another aspect, a computer implemented method for determining an efficacy of a treatment in a trial includes co-registering images corresponding to a same region of a subject to a baseline image via a single affine registration by way of computer. The images are acquired at different times after administering a trial treatment to the subject. The method further includes applying a computer implemented transformation to  
30 the co-registered images to fit the co-registered images to an anatomical model representing the anatomical region under consideration. The method further includes generating a value representing a physiological change in the region of interest based on

the mapped co-registered images. The method further includes determining an efficacy of the treatment based on the value.

In another aspect, a system includes a trial population estimator that generates a first signal indicative of an estimated trial population size based on a given statistical power and an image analysis algorithm. The algorithm includes transforming co-registered images of a same region of interest of a subject administered a trial treatment to a model based on a same transformation. The system further includes a trial cost estimator that generates a second signal indicative of an estimated clinical trial cost as a function of the estimated trial population size, and a service that provides the second signal to a client over a computer network.

In another aspect, a system includes a service that generates a signal indicative of a trial image analysis algorithm based on a trial budget and a statistical power, both provided by a client over a network, wherein the algorithm includes transforming co-registered images of a same region of interest of a subject administered a trial treatment to a model based on a same transformation, and the service provides the signal to the client over the network.

Still further aspects of the present disclosure will be appreciated to those of ordinary skill in the art upon reading and understand the following detailed description.

The disclosure may take form in various components and arrangements of components, and in various steps and arrangements of steps. The drawings are only for purposes of illustrating the preferred embodiments and are not to be construed as limiting the disclosure.

FIGURE 1 illustrates an example clinical trial flow diagram.

FIGURE 2 illustrates a first example image standardization technique.

FIGURE 3 illustrates a second example image standardization technique.

FIGURE 4 shows an example of co-registering images for a subject.

FIGURE 5 shows an example of transforming a co-registered image.

FIGURE 6 illustrates a clinical trial planning service.

FIGURE 1 illustrates an example clinical trial flow diagram. The illustrated flow diagram provides for increased clinical trial statistical power or reduced clinical trial population for a given statistical power by decreasing clinical trial data variability.

At 102, a treatment for clinical trial such as a new pharmaceutical or device is identified. One or more preliminary experiments can be conducted to gain insight for the planning of the clinical trial. This may include obtaining information about characteristics of suitable subjects for the trial (the trial population), comparative data such as alternative treatments and/or a placebo, clinical trial budgets, etc.

At 104, a treatment hypothesis is determined. The hypothesis may include predicting results, determining a desired outcome, etc.

At 106, a desired statistical power is set for the trial. The statistical power provides a quantitative measure of the ability of the trial to reliably detect the affect of the treatment.

At 108 an image analysis algorithm for the trial is identified based on the  
5 statistical power. In one instance, the algorithm includes affinely co-registering images for a subject of the trial and subsequently stereotactically normalizing each of the co-registered images based on an average image, as described in greater detail below in connection with FIGURE 2. In another example, the algorithm includes affinely co-registering images for the subject and subsequently stereotactically normalizing each of the co-registered images  
10 based on a reference, as described in greater detail below in connection with FIGURE 3.

The approaches of FIGURES 2 and 3 utilize a single estimated non-rigid (elastic) registration transformation to transform affinely co-registered images and can improve the statistical power of a clinical trial for a given trial population size relative to a configuration in which non-aligned (non co-registered) images are individually  
15 transformed via different non-rigid (elastic) registrations as the approaches of FIGURES 2 and 3 add relatively less variance to the post-processed images and thus provide relatively higher statistical power for the clinical trial. Alternatively, the trial population size can be reduced for a given statistical power. Individually transforming non co-registered images using different elastic registrations is not as accurate and adds more variation (noise) to the  
20 processed images, which decreases statistical power.

At 110, a trial population size is determined based on the statistical power and the analysis algorithm. The size of the population generally increases with increasing variability and thus can be decreased using the algorithms of FIGURES 2 and 3.

At 112, an estimated cost of the trial is determined as a function of the  
25 population size.

At 114, it is determined whether the estimated cost is less than a target population cost ( $T_{cost}$ ) of the trial. Alternatively, the estimated cost is added with the other costs of the trial and the aggregated cost is compared with the trial budget.

In this example, if the estimated cost is greater than the target cost, then the  
30 trial is not conducted and flow ends at 116, and if the estimated cost is less than the target cost, then the trial proceeds.

At 118, the trial and alternative/control treatments are administered to the subjects. By way of example, the trial treatment can be administered to a first group of the subjects. A placebo can be administered to a second different group of the subjects. Alternatively or additionally, one or more alternative treatments can be administered to one  
5 or more other groups.

At 120, the subjects are monitored over time. In one embodiment, this includes acquiring image data through periodically scanning or imaging the subjects over some time during such as hours, days, weeks, months or years. For example, in one instance baseline images for the subjects are acquired before, during or shortly after  
10 administration of the trial treatment, alternative treatment and/or placebo.

Post trial treatment, alternative treatment and/or placebo administration image data or images generated therefrom are subsequently obtained over the trial period. The image can be a positron emission tomography (PET), single photon emission computed tomography (SPECT), computed tomography (CT), magnetic resonance (MR),  
15 ultrasound (US), other medical and/or non-medical image.

At 122, the resulting images for each subject are standardized in accordance with the image analysis algorithms identified at 108 as described in greater detail below. As noted above, examples of such algorithms are described in connection with FIGURES 2 and 3. The images can be presented for display on a display of a computing device before  
20 and/or after standardization.

At 124, the results of the trial are analyzed. In one instance, this includes performing a computer based statistical analysis. The statistical analysis may include determining a physiological (structural and/or functional) change for a region of interest over time for each subject via the standardized images. This includes measuring and  
25 recording a value representing a change between the images for each patient over time. The value may include information such a color or gray scale value representing a degree of change.

The value may be presented visually or graphically through one or more images and/or numerically through numeric characters. The identified change may  
30 correspond to a particular region of interest selected by a user or otherwise, and may include a single voxel, a plurality of voxels, or the entire image. The displayed image may

only show pixels corresponding to changes greater than a threshold value, may highlight or otherwise emphasize pixels corresponding to changes greater than a threshold value, etc.

At 126, the treatment is assessed based on the analyzed results. For example, the results can be used to assess the safety and effectiveness of the new medication or device on a specific kind of patient, of a different dose of a medication than that commonly used, of an already marketed medication or device for a new indication, to determine whether the new medication or device is more effective for a patient's condition than an already used, standard medication or device, etc. For example, if the difference is greater than a hypothesized difference, then the hypothesis is confirmed, and if the difference is less than the hypothesized difference, then the hypothesis is rejected.

FIGURE 2 illustrates an example image standardization technique that can be employed in connection with act 122 of FIGURE 1. The technique includes generating a single estimated elastic transformation based on an average of co-registered images and applying this estimated elastic transformation to each of the co-registered images.

At 202, the images for each subject are co-registered with each other using an affine registration. In one non-limiting instance, this includes identifying one of the images as a reference or baseline image, and the other images are co-registered to the reference image. The reference image can be the first image in time, the last image in time, or any image therebetween. The reference image may be manually selected by a user and/or automatically selected via computer executable instructions being executed by a computer processor.

Generally, prior to co-registration the images for a subject are not-aligned with respect to each other. During registration, the images are rotated and/or translated and/or geometrically scaled with respect to the reference image so that the anatomy therein is aligned. FIGURE 4 shows an example in which a series of three non-aligned images are co-registered. The depicted 2-dimensional image is a representation of a 3-dimensional image. In this example, an image 402 is selected as the reference or baseline image, and images 404 and 406 are registered with the image 402 based on respective registration transformation R1 and R2 to produce co-registered images 402, 406 and 408.

Returning to FIGURE 2, at 204 an average image is generated. The average image is an average of the co-registered images and can be generated by summing the co-registered images and dividing the summation by the total number of summed images.

At 206 a stereotactic normalization elastic transformation is generated based on the average image and a model of anatomy of interest. In one instance, the transformation represents a mapping between the average image and an anatomical model of interest. A suitable transformation maps each image pixel to a known anatomical  
5 position.

At 208, the elastic transformation is applied to each of the co-registered images. The transformation elastically transforms or warps each of the co-registered images to fit the model.

FIGURE 5 shows an example in which a co-registered image 502 is  
10 transformed with a transformation 504 to generate a standardized image 506. In this example, the transformation 504 is based on a template image 508.

The resulting stereotactically normalized co-registered images can be analyzed as discussed above in connection with 124.

FIGURE 3 illustrates an example image standardization technique that can  
15 be employed in connection with act 122 of FIGURE 1. The technique includes generating a single estimated elastic transformation based on a reference or baseline co-registered image and applying the estimated elastic transformation to the co-registered images.

At 302, similar to 202, the images for a subject are co-registered with each other using a rigid registration.

At 304, one of the images is used to generate the stereotactic normalization  
20 transformation. The image may be the reference image for the co-registration or a different image. As discussed above, the transformation represents a mapping between the image and an anatomical model. Note that if the first image in time is used to generate the transformation, steps 302 and 304 may be exchanged in order, i.e. 304 first, then 302 for  
25 each additional image of the same subject.

At 306, each co-registered image is transformed via the same stereotactic normalization transformation. The co-registered images can be transformed in parallel, for example, once all of the images are acquired, or sequentially as images are obtained.

The resulting stereotactically normalized co-registered images can be  
30 analyzed as discussed above in connection with 124.

The approach of FIGURE 2 generally provides higher statistical power relative to the approach of FIGURE 3. However, if additional images are acquired for a

subject after the elastic transformation is generated, then the transformation is re-calculated to take into account the later acquired images.

As discussed herein, the approaches of FIGURES 2 and 3 may facilitate reducing trial population size and thus trial cost by improving statistical power through reducing variability in measurement. The following provides a non-limiting example. Assume a two-sided significance level ("p-value") of 0.05, a statistical power requirement of 0.8, and a hypothesized effect size of 10% between 2 groups of equal size. Also assume a mean outcome measure of 0.01 ( $\Rightarrow \Delta = 0.001$ ), with a standard deviation of 0.014 using the approaches of FIGURES 2 and 3 and a standard deviation of 0.015 using an approach where the images are not co-registered and each image is individually transformed with its own transformation. An approximated population size for the approaches of FIGURES 2 and 3 is 3078, whereas an approximated population size for the other approach is 3533. Hence, using the approaches of FIGURES 2 and 3 would reduce the trial population size relative to the other approach.

Those of ordinary skill in the art will recognize that the various techniques described herein may be implemented by way of computer readable instructions stored on a computer readable storage medium accessible to a computer processor. When executed, the instructions cause the processor(s) to carry out the described techniques. Note that the medium need not be local to the processor; the instructions may be downloaded or otherwise accessed via a communication network such as the internet. The relevant computers may also be located remote from the imaging system, with the scan data transferred via a suitable network or other medium.

FIGURE 6 illustrates an example clinical trial planning service. As shown, a clinical trial client 602 provides clinical trial information to a service 604, which estimates a cost of the clinical trial based on the clinical trial information. In the illustrated example, the client 602 and the service 604 communicate electronically, via wire or wirelessly, through a computer network 610 such as the Internet, an intranet, etc. The service 604 may be subscription or otherwise based.

The clinical trial client 602 may be a financial or accounting client or other client that may determine or influence whether a clinical trial is conducted or not. In one instance, the clinical trial client 602 provides information such as a desired clinical trial statistical power, an algorithm used to analyze the data, and/or known variations with the

algorithm. The algorithm may be a statistical power enhancing algorithm such as those described in connection with FIGURES 1-3 above.

This information is provided to a clinical trial population determiner 606, which estimates the population for the trial based on the desired statistical power, the  
5 algorithm used to analyze the data, and/or the known variations. A cost estimator 608 estimates a cost of the trial as a function of trial population. A signal indicative of the cost estimate is provided to the clinical trial client 602 by the service 604. The cost estimate may include alternatives such as a cost estimate for a clinical trial with greater statistical power due to the analysis algorithm and a cost estimate for a clinical trial with a reduced  
10 population at the desired statistical power due to the analysis algorithm.

In another embodiment, the clinical trial client 602 provides information such as a desired clinical trial statistical power and a budget allocated for a trial population, and the service 602 determines a suitable algorithm(s) and/or an estimated population size based on the information. The service 604 provides one or more signals indicative of the  
15 suitable algorithm(s) and/or the estimated population size to the client 602. In this embodiment, the cost estimator 608 can be omitted.

The disclosure has been described with reference to various embodiments. Modifications and alterations may occur to others upon reading the detailed description. It is intended that the disclosure be constructed as including all such modifications and  
20 alterations insofar as they come within the scope of the appended claims or the equivalents thereof.

CLAIMS

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method for assessing a treatment under trial, comprising:  
obtaining images generated from image data acquired at different times during a trial time period for a same anatomical region of a subject, wherein the treatment is administered to the subject for the trial;  
co-registering the images using a single transformation;  
mapping the co-registered images to a reference image representing the anatomical region;  
generating a trial image of the anatomical region showing at least one of structural or functional physiological changes that occurred during the trial time period based on the mapped co-registered images; and  
displaying the trial image.
2. The method of claim 1, further including performing a statistical analysis over the trial image and trial images for one or more other subjects receiving an alternative treatment or a placebo to assess efficacy of the treatment under trial.
3. The method of claim 1, further comprising: selecting one of the images as a baseline image; wherein co-registering the images includes co-registering the images with the selected baseline image.
4. The method of any of claims 1 to 3, further comprising:  
generating an average image based on the co-registered images; and  
generating a transformation based on the average image; wherein mapping the co-registered images includes transforming the co-registered images with the generated transformation.
5. The method of any of claims 1 to 3, further comprising:  
selecting one of the co-registered images as a reference image; and

generating a transformation based on the reference image; wherein mapping the co-registered images includes transforming the co-registered images with the generated transformation.

6. The method of any of claims 4 to 5, further comprising: generating the transformation based on an anatomical model representing the region of interest.
7. The method of claim 6, wherein the anatomical model is a three dimensional volume.
8. The method of any of claims 6 to 7, wherein the transformation warps the co-registered images to fit the model.
9. The method of any of claims 1 to 8, further comprising: performing a computer based statistical analysis on the mapped co-registered images; wherein displaying the trial image includes displaying an image that emphasizes pixels corresponding to structural or functional changes greater than a predetermined threshold change based on the statistical analysis.
10. The method of any of claims 1 to 9, wherein the trial image is a surface projection onto a surface of the anatomical region.
11. The method of claim 9, wherein performing the statistical analysis includes determining a value representing the structural or functional change; and comparing the value with the predetermined threshold, wherein the displayed image only shows pixels with corresponding values that are greater than the predetermined threshold.
12. The method of claim 9, wherein performing the statistical analysis includes determining a value representing the structural or functional change; and comparing the value with the predetermined threshold, wherein the displayed image visually highlights pixels with corresponding values that are greater than the predetermined threshold.

13. The method of any of claims 9 to 12, wherein performing the statistical analysis includes comparing the trial image with an image generated with data obtained for a second subject receiving a placebo.

14. The method of any of claims 9 to 13, wherein performing the statistical analysis includes comparing the trial image with an image generated with data obtained for a second subject receiving a second treatment.

15. The method of any of claims 1 to 14, further comprising determining an efficacy of the administered treatment based on the trial image.

16. A method for assessing a treatment under trial substantially as hereinbefore described with reference to the accompanying drawings.




Fig. 1




Fig. 2




Fig. 3




Fig. 6




Fig. 4




Fig. 5